Who Exports Osimertinib from India — 15 Suppliers Behind a $1.1M Market
India's osimertinib export market is supplied by 15 active exporters who collectively shipped $1.1M across 130 shipments. NIVIRA EXPORTS leads with a 31.9% market share, followed by NU HOSPITALS PRIVATE LIMITED and IKRIS PHARMA NETWORK PRIVATE LIMITED. The top 5 suppliers together control 60.6% of total export value, reflecting a concentrated market structure.
Top Osimertinib Exporters from India — Ranked by Export Value
NIVIRA EXPORTS is the leading osimertinib exporter from India, holding a 31.9% share of the $1.1M market across 130 shipments from 15 exporters. The top 5 suppliers — NIVIRA EXPORTS, NU HOSPITALS PRIVATE LIMITED, IKRIS PHARMA NETWORK PRIVATE LIMITED, MATSUN EXPORTS, YARAPMIN PHARMA PRIVATE LIMITED — collectively control 60.6% of total export value, indicating a moderately concentrated market. Individual shares are: NIVIRA EXPORTS (31.9%), NU HOSPITALS PRIVATE LIMITED (12.0%), IKRIS PHARMA NETWORK PRIVATE LIMITED (7.0%), MATSUN EXPORTS (5.2%), YARAPMIN PHARMA PRIVATE LIMITED (4.5%).
Top Osimertinib Exporters from India
Ranked by export value · 15 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | NIVIRA EXPORTS | $347.1K | 1 | 31.9% |
| 2 | NU HOSPITALS PRIVATE LIMITED OSIMERTINIB - TABLETS - 80MG - TAGRISSOOSIMERTINIB - TABLETS- 80MG - TAGRISSO | $130.8K | 1 | 12.0% |
| 3 | IKRIS PHARMA NETWORK PRIVATE LIMITED | $76.3K | 1 | 7.0% |
| 4 | MATSUN EXPORTS | $57.1K | 1 | 5.2% |
| 5 | YARAPMIN PHARMA PRIVATE LIMITED | $49.5K | 1 | 4.5% |
| 6 | VAMA LIFECARE PRIVATE LIMITED | $43.1K | 1 | 4.0% |
| 7 | SPECIALITY MEDICINES PRIVATE LIMITED | $27.8K | 1 | 2.5% |
| 8 | GLOBYZ BIOPHARMA PRIVATE LIMITED | $19.5K | 1 | 1.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Osimertinib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| NIVIRA EXPORTS | Not Listed | Yes | Yes | Not verified | Nivira Exports collaborates with manufacturers accredited with WHO-GMP, EU-GMP, |
TransData Nexus reviewed the regulatory standing of 1 leading Osimertinib exporters from India. 0 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 1 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Osimertinib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in research and development. This robust infrastructure makes Hyderabad a prime location for sourcing high-quality APIs, including Osimertinib.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with companies like Zydus Cadila and Torrent Pharmaceuticals headquartered in this region. The well-established infrastructure and regulatory compliance make this cluster ideal for sourcing finished formulations of Osimertinib.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. Mumbai, being India's financial capital, offers extensive logistics and shipping facilities, facilitating efficient international distribution. This region's strategic location and infrastructure support the export of pharmaceuticals, including Osimertinib, to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives and government policies. The region houses over 1,000 pharmaceutical units, making it one of the largest pharmaceutical hubs in Asia. Its cost-effective manufacturing capabilities make it a viable option for sourcing Osimertinib.
5Sourcing Recommendations
- Evaluate Supplier Credentials: Prioritize suppliers with established reputations and compliance with regulatory standards to ensure the quality and efficacy of Osimertinib.
- Assess Manufacturing Capabilities: Consider suppliers with robust manufacturing facilities and capacity to meet demand, particularly those located in Hyderabad for APIs and Ahmedabad-Vadodara for formulations.
- Verify Export Experience: Select suppliers with proven experience in exporting pharmaceuticals, especially those based in the Mumbai-Thane-Raigad region, to ensure smooth international logistics.
- Consider Cost Advantages: Explore sourcing options from the Baddi-Nalagarh cluster to leverage potential cost benefits due to tax incentives and lower manufacturing costs.
By strategically selecting suppliers from these specialized clusters, TransData Nexus can optimize the sourcing of Osimertinib, ensuring quality, compliance, and cost-effectiveness.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Osimertinib exporters from India
Torrent Pharmaceuticals Limited — Torrent Pharma acquires controlling stake in J.B. Chemicals & Pharmaceuticals
Torrent Pharmaceuticals Limited announced the acquisition of a 46.39% equity stake in J.B. Chemicals & Pharmaceuticals from KKR, followed by a merger of the two entities. This strategic move aims to strengthen Torrent's presence in the Indian pharmaceutical market and expand its contract development and manufacturing organization (CDMO) capabilities.
Impact: While this acquisition does not directly involve the top Osimertinib exporters, it reflects a trend of consolidation in the Indian pharmaceutical industry, potentially affecting market dynamics and competitive landscapes for Osimertinib exports.
Windlas Biotech Limited — Windlas Biotech ventures into injectable product manufacturing
Windlas Biotech Limited announced its strategic expansion into the injectables segment, aiming to diversify its product portfolio beyond oral solids and liquids. The new injectables facility has received customer approvals and will cater to all three business verticals: CDMO, trade generics, and exports.
Impact: This expansion signifies a growing trend among Indian pharmaceutical companies to enhance their manufacturing capabilities, which could influence the competitive environment for Osimertinib exporters.
Piramal Pharma Limited — Piramal Pharma addresses challenges in CDMO segment
Piramal Pharma Limited reported facing execution challenges, high attrition at overseas sites, and margin impacts from higher raw material costs in its CDMO business over the last 12-18 months. The company has initiated measures to resolve these issues, including rehiring and training personnel, resuming customer audits, and bringing new capital expenditures online in FY24.
Impact: These challenges highlight the complexities within the CDMO sector, potentially affecting the supply chain and export capabilities of pharmaceutical products like Osimertinib.
Common Questions — Osimertinib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which osimertinib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, NIVIRA EXPORTS leads with 52 recorded shipments worth $347.1K. NU HOSPITALS PRIVATE LIMITED (4 shipments) and IKRIS PHARMA NETWORK PRIVATE LIMITED (17 shipments) are also established high-volume exporters.
Q How many osimertinib manufacturers are there in India?
India has 15 active osimertinib exporters with a combined export market of $1.1M across 130 shipments to 8 countries. The top 5 suppliers hold 60.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for osimertinib from India?
Average FOB unit price: $2290.13 per unit, ranging from $0.02 to $5448.41. Average shipment value: $8.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 15 verified Indian exporters of Osimertinib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 130 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 8 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
130 Verified Shipments
15 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists